Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 14 HR+/HER2- Advanced Breast Cancer 2 Triple Negative Breast Neoplasms 1 HR Positive HER2 Negative Advanced Breast Cancer 1 HER2-positive Breast Cancer 1 Breast Diseases 1 Brain Neoplasms 1 Advanced Breast Cancer 1

Interventions

Letrozole 5 Fulvestrant 5 trastuzumab deruxtecan 3 Injections 3 toripalimab 2 sacituzumab govitecan 2 palbociclib 2 elacestrant 2 abemaciclib 2 Anastrozole 2 AZD9833 2 ribociclib 1 pyrotinib 1 exemestane 1 eribulin 1 disitamab vedotin 1 dalpiciclib 1 Vinorelbine 1 Selective Estrogen Receptor Modulators 1 Ritonavir 1 RAD1901 1 Paclitaxel 1 Lead 1 Itraconazole 1 Goserelin 1 Gonadotropin-Releasing Hormone 1 Everolimus 1 Docetaxel 1 Bevacizumab 1 Aromatase Inhibitors 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Breast Cancer × dalpiciclib × 1 year × Clear all

NCT06301438 2026-02-03

Dalpiciclib in HR+/HER2- ABC

RenJi Hospital

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡